Phaseline

Targets › MAGL

MAGL: drug programs, companies and trials

2 programs from 2 companies in 4 trials: 3 Phase 2, 1 Phase 1; Neurology, Other; next expected readout Dec 2026.

Open in Phaseline: the race on MAGL, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Bristol-Myers SquibbIrafamdastat (BMS-986368, CC-97489)
FAAH/MAGL inhibitor
FAAH, MAGLPhase 2Multiple Sclerosis Spasticity; Agitation; Healthy VolunteersDec 2026
Alberto EsquenaziBMS-986368
FAAH/MAGL inhibitor
FAAH, MAGLPhase 2Post-Stroke SpasticityJun 2027

Conditions

Post-Stroke Spasticity (1) Multiple Sclerosis Spasticity (1) Agitation (1) Healthy Volunteers (1)

Modalities

small molecule (2)

Companies

Alberto Esquenazi (1) Bristol-Myers Squibb (1)

Related targets

FAAH (2)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.